secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001171843-22-005501
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Q2 net loss $6.1M; cash $29.8M; DARPA selects AgenT-797; clinical data updates expected 2H22
--------------------------------------------------------------------------------

- Cash $29.8M as of June 30, 2022, down from $38.9M at Dec 31, 2021; cash used in ops $4.6M for Q2.
- Net loss $6.1M ($0.18/share) vs $6.3M ($0.26/share) in Q2 2021; R&D spend $5.9M vs $3.6M.
- AgenT-797 clinical data updates in solid tumors, myeloma and viral ARDS planned for 2H2022.
- AgenT-797 identified as selectable for DARPA funding; contract negotiations underway.
- Internal cGMP manufacturing completed with capacity to treat >700,000 patients/year; Dr. Joy Zhou appointed VP CMC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000117184322005501/0001171843-22-005501-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000117184322005501/f8k_080922.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-005501

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer